Jyong Biotech Plans Texas Facility for Potential Drug Candidates

New Taipei City, Taiwan, Oct. 15, 2026 /CourierPR/ -- Jyong Biotech Ltd., a science-driven biotechnology company based in Taiwan, announced plans to establish a potential new manufacturing facility and U.S. operations center in Texas. The initiative aims to support the company's U.S. operations and position it for the potential future commercialization of its proprietary investigational drug candidates, should they be approved.

The company selected Texas based on several factors, including competitive land costs, a favorable corporate tax structure, state tax exemptions, and manufacturing incentives.

Jyong Biotech's commercial strategy in the U.S. targets a significant patient population. According to a 2012 review published in the Canadian Urological Association Journal, approximately 8.7 million American men are potential candidates for treatment of BPH-related LUTS each year. A 2015 review published in The Canadian Journal of Urology reported that as of 2015, approximately 12.2 million U.S. men were actively managed for BPH/LUTS. Based on this review, the company believes there is a potential commercial opportunity across the following segments:

- Watchful-Waiting Population: Approximately 35% of actively managed patients are in watchful waiting and receive no pharmacological therapy, and represent the company's intended primary target population, if new drug candidate is approved. - Discontinued Treatment Population: An estimated 9.1% of actively managed patients have discontinued drug therapy and returned to watchful waiting, representing a potential secondary target population. - Current Treatment Population: For the 54.8% of actively managed patients taking chemical medications, the company believes new drug candidate, if approved, could potentially be evaluated as a combination or alternative therapy.

As of the date of this press release, Jyong Biotech does not have any approved drug products available for commercial use in any jurisdiction. The company is currently in the process of submitting a facility and operations plan to local government authorities in the State of Texas and is preparing to commence formal communications with the relevant government agencies regarding the relevant procedures.

Since its inception in 2002, Jyong Biotech has built integrated capabilities that encompass all key functionalities of drug development, including early-stage drug discovery and development, pharmacology, toxicology, clinical trials, regulatory affairs, manufacturing, and commercialization. The company specializes in the treatment of urinary system diseases and has been developing a series of botanical drug candidates, including its primary botanical drug candidate, BOTRESO®, another clinical-stage botanical drug candidate, and other preclinical-stage botanical drug candidates.

The U.S. is Jyong Biotech's highest-priority market due to favorable drug pricing dynamics and the broader international recognition of FDA-approved pharmaceuticals. The company believes that FDA approvals for its product candidates, if obtained, may facilitate regulatory filings in other markets; however, approval in any other jurisdiction is not assured.